Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycoses in AIDS.

B Dupont1, H H Crewe Brown, K Westermann

  • 1Unité de Mycologie, Institut Pasteur, H pital Necker, Paris, France. bdupont@pasteur.fr

Medical Mycology
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intercellular adhesion molecule-1 deficiency protects MRL/MpJ-Fas(lpr) mice from early lethality.

Journal of immunology (Baltimore, Md. : 1950)·1997
Same author

Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir.

AIDS (London, England)·1997
Same author

Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates.

AIDS (London, England)·1997
Same author

Antifungal prophylaxis during neutropenia and immunodeficiency.

Clinical microbiology reviews·1997
Same author

Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.

Archives of dermatology·1997
Same author

Search for infectious HIV in gingival crevicular fluid and saliva of advanced AIDS patients with severe periodontitis.

AIDS (London, England)·1997
Same journal

Diagnostic performance of IgG against multiplex Aspergillus antigens (mx4) for identifying chronic pulmonary aspergillosis.

Medical mycology·2026
Same journal

The clinical utility of bronchoalveolar lavage galactomannan result stewardship within a tertiary medical system.

Medical mycology·2026
Same journal

Cross-reactivity of Cryptococcal Antigen Lateral Flow Assay with Basidiomycetous Yeasts.

Medical mycology·2026
Same journal

Cryptococcus gattii complex infections in southern Brazil: epidemiology, clinical features, management and outcomes from a 33-year cohort.

Medical mycology·2026
Same journal

HAC1 contributes to stress adaptation and virulence in the emerging fungal pathogen Candida auris.

Medical mycology·2026
Same journal

Multicenter Study Reveals Alarming Terbinafine Resistance in Trichophyton indotineae Isolates from Iran.

Medical mycology·2026
See all related articles

Highly active antiretroviral therapy (HAART) has significantly reduced opportunistic infections (OI) in AIDS patients, making prophylaxis for some infections unnecessary. However, OI epidemiology varies globally, especially in resource-limited settings.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • Opportunistic infections (OI) are a major concern in patients with acquired immune deficiency syndrome (AIDS).
  • Highly active antiretroviral therapy (HAART) has transformed AIDS management and OI epidemiology.
  • Global access to HAART is unequal, leading to disparate OI patterns.

Purpose of the Study:

  • To analyze the changing epidemiology of OI in AIDS patients on HAART.
  • To evaluate the impact of HAART on OI incidence and antifungal resistance.
  • To compare OI epidemiology in high-income versus low-income settings.

Main Methods:

  • Review of epidemiological data on OI in AIDS patients.
  • Analysis of clinical outcomes related to OI and antifungal resistance.

Related Experiment Videos

  • Comparative analysis of OI patterns in different healthcare settings.

    • Main Results:

    • A significant decrease in both minor and major OI was observed in patients receiving HAART.
    • Clinical resistance of thrush to antifungal agents has become rare.
    • Prophylaxis for Pneumocystis carinii pneumonia can be discontinued, but recommendations for other OI remain unclear.

    Conclusions:

    • HAART has dramatically altered OI epidemiology, reducing their incidence and severity.
    • Antifungal resistance in common OI like thrush has decreased with HAART.
    • Disparities in HAART access create vastly different OI challenges in various global regions, necessitating tailored public health strategies.